Skip to main content

Ukoniq Side Effects

Generic name: umbralisib

Medically reviewed by Drugs.com. Last updated on Mar 11, 2024.

Note: This document contains side effect information about umbralisib. Some dosage forms listed on this page may not apply to the brand name Ukoniq.

Applies to umbralisib: oral tablet.

Warning

Umbralisib affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, cough, or other flu-like symptoms

Get emergency medical help if you have signs of a severe skin reaction such as a fever with skin rash, itching, blistering, peeling, or sores on your skin or mouth.

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include: skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.

Call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to umbralisib: oral tablet.

Hematologic

Very common (10% or more): Decreased neutrophil decreased (33%), decreased hemoglobin (27%), decrease platelets (26%)

Common (1% to 10%): Transaminase elevation, neutropenia

Frequency not reported: Anemia, thrombocytopenia[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (27%)[Ref]

Metabolic

Very common (10% or more): Decreased appetite (19%), decreased potassium (21%)[Ref]

Psychiatric

Very common (10% or more): Insomnia (14%)[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Hepatic

Very common (10% or more): Increased alanine aminotransferase (33%), increased aspartate aminotransferase (32%)[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infection (21%)

Common (1% to 10%): Pneumonia, dyspnea

Rare (less than 0.1%): Pneumonitis[Ref]

General

Very common (10% or more): Pyrexia (10%)

Common (1% to 10%): Sepsis[Ref]

Nervous system

Very common (10% or more): Fatigue (41%)[Ref]

Renal

Very common (10% or more): Increased creatinine (79%)[Ref]

Cardiovascular

Very common (10% or more): Edema (14%)[Ref]

Dermatologic

Very common (10% or more): Rash (18%)

Rare (less than 0.1%): Exfoliative dermatitis[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (58%), nausea (38%), vomiting (21%), abdominal pain (19%)

Common (1% to 10%): diarrhea, colitis[Ref]

References

1. Product Information. Ukoniq (umbralisib). TG Therapeutics. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.